Annual Meeting Highlights Latest Clinical Hypertension Research

May 6 - 9, 2009San Francisco Marriott55 Fourth StreetSan Francisco, CA

Newswise — In addition to highlighting the latest clinical research, this year's meeting will provide insights into anticipated updates to hypertension treatment guidelines and data exploring health disparities and proposed solutions. ASH is also proud to present its second Hypertension Community Outreach Initiative, as part of the San Francisco Cinco de Mayo festival, which will provide hypertension screening and education to empower local San Franciscans to take control of their cardiovascular health.

Press Briefing Schedule

Highlights of ASH - Wednesday, May 6 (10:00-11:00am)"¢ New Guidelines Update: Where Are We Going?"¢ Awareness, Treatment and Control of Hypertension in China"¢ Meta-analyses of Clinical Trial Data: Implications for Treatment

New Study Findings - Thursday, May 7 (10:00-11:30am) "¢ An Analysis of Treating BP to New Targets: How Low Should You Go? "¢ Treatment Resistant Hypertension in a Community-Based Practice Network"¢ Multiple Risk Factor Control in Diabetic, Dyslipidemic Hypertensive Patients "¢ Is Blood Pressure Variability During Childhood Associated with Adult Hypertension in Blacks and Whites?"¢ Is the Association of Birth Weight with Blood Pressure Amplified with Increasing Age?"¢ Is HTN From Adolescence Predictive of Later LVH?"¢ Prevalence of Hypertension in Urban Boston Female Population: A Family Van Mobile Health Model"¢ Patient Use of and Satisfaction with a Web-Based Pharmacist Intervention to Improve Hypertension Control

Lunch with the Experts - Thursday, May 7 (12:00-1:00pm)"¢ Academic Medicine and the Economy: What Would Darwin Advise?"¢ Proposed ASH Changes to Health Care Provider Specialty Code for "Hypertension Specialists"

Late Breaker and New Insights from Clinical Trials - Friday, May 8 (1:00-2:00pm)"¢ The Non-dipping Phenomenon and Coronary Artery Disease in Men: An Association or an Independent Risk Factor?"¢ Fixed Doses of Darusentan Compared to Placebo in Treatment Resistant Hypertension"¢ Comparable Blood Pressure Control and LV Mass Reduction in Patients with Hypertension and LVH with ACE Inhibitor Alone or Combined with β-Blockade"¢ Effect of Blood Pressure Lowering on Diastolic Function in Patients with Uncontrolled Hypertension and Diastolic Dysfunction "¢ A Comparison of 24-Hour Ambulatory and Clinic Blood Pressure Readings in the ACCOMPLISH Trial"¢ Are Dose-Dependent Blood Pressure Lowering Effects by a Dual Angiotensin and Endothelin Receptor Antagonist Better than Irbesartan in Stage I and II Hypertensive Patients?

To register for the meeting or to receive embargoed materials, please contact the Press Room Managers:

Katherine Vince ASH 2009 Press Room Manager Chamberlain Healthcare Public Relations Tel: 1 212-884-0668 Fax: 1 212-884-0628[email protected]

Vanessa Leon ASH 2009 Press Room Manager Chamberlain Healthcare Public Relations Tel: +44 (0) 7885 485 103 Fax: 1 212-884-0628[email protected]

About the American Society of Hypertension: The American Society of Hypertension (ASH) is the largest U.S. professional organization of scientific investigators and healthcare professionals committed to eliminating hypertension and its consequences. ASH is dedicated to promoting strategies to prevent hypertension and to improving the care of patients with hypertension and associated disorders. The Society serves as a scientific forum that bridges current hypertension research with effective clinical treatment strategies for patients.